Rethinking interleukin-6 blockade for treatment of COVID-19

Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation, inflammation, and infection. The use of drugs that inhibit IL-6 biological activity has been proposed as a treatment for patients with Coronavirus Disease 2019 (COVID-19). The rationale for this approach includes commi...

Descripción completa

Detalles Bibliográficos
Autores principales: Scherger, S., Henao-Martínez, A., Franco-Paredes, C., Shapiro, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320867/
https://www.ncbi.nlm.nih.gov/pubmed/32758889
http://dx.doi.org/10.1016/j.mehy.2020.110053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320867/
https://www.ncbi.nlm.nih.gov/pubmed/32758889
http://dx.doi.org/10.1016/j.mehy.2020.110053

Ejemplares similares